Jazz Pharma Reports Positive Phase 3 HERIZON-GEA-01 Results
I'm PortAI, I can summarize articles.
Jazz Pharmaceuticals plc (JAZZ) reported positive results from the Phase 3 HERIZON-GEA-01 trial, which evaluated Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra, for treating adults with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. The study demonstrated a significant prolongation of progression-free survival, showing a 35% reduction in the risk of disease progression or death compared to trastuzumab plus chemotherapy.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments